MARKET

PTIX

PTIX

Protagenic Therapeutics Inc
NASDAQ
1.290
-0.080
-5.84%
Closed 19:31 12/18 EST
OPEN
1.410
PREV CLOSE
1.370
HIGH
1.410
LOW
1.250
VOLUME
69.96K
TURNOVER
0
52 WEEK HIGH
14.28
52 WEEK LOW
1.250
MARKET CAP
2.50M
P/E (TTM)
-0.5592
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PTIX last week (1208-1212)?
Weekly Report · 4d ago
Protagenic reports results from Phase 1 multiple-dose study of PT00114
TipRanks · 12/09 13:55
Protagenic Therapeutics Reports Topline Phase 1 Safety Data For PT00114, Was Well Tolerated Across All Dose Ranges Studied; Paves Way For Phase 2 In Stress-Related Neuropsychiatric Conditions
Benzinga · 12/09 13:48
Protagenic Therapeutics Reports Positive Phase 1 Results for PT00114 in Stress-Related Psychiatric Disorders
Reuters · 12/09 13:46
Weekly Report: what happened at PTIX last week (1201-1205)?
Weekly Report · 12/08 09:54
Protagenic Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting
Reuters · 12/05 21:53
Weekly Report: what happened at PTIX last week (1124-1128)?
Weekly Report · 12/01 09:51
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 11/28 12:05
More
About PTIX
Protagenic Therapeutics, Inc. is a neuroactive biopharmaceutical company. The Company has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The Company's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The Company's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The Company's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models.

Webull offers Protagenic Therapeutics Inc stock information, including NASDAQ: PTIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTIX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTIX stock methods without spending real money on the virtual paper trading platform.